Dexlansoprazole (DSP) is a proton pump inhibitor, it used to treat GERD and ulcer colitis. DSP works by decreasing the volume of acid in the stomach. DSP is an acid-labile medication that may be destroyed in the stomach's acidic pH. A coating technique was used to postpone drug release in the stomach, which can extend pharmacological activity. Shellac can be used to develop the sustain release tablet of dexlansoprazole as retardation of the drug (dexlansoprazole) was observed in the acidic pH of the stomach, and hence a sustain coated dexlansoprazole tablet was prepared and evaluated. The coating's primary function is to allow for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits fast...
Targeted release of bilayer tablet for combination therapy of pantoprazole sodium and ondansetron hy...
Duodenal ulcers are part of a broader disease state categorized as peptic ulcer diseaseWhile most du...
Background: The pharmacokinetics and pharmacodynamics of a novel orally disintegrating tablet (ODT) ...
The goal of this study is to develop a long-acting Lansoprazole delivery system. Lansoprazole belong...
proton pump inhibitor belongs to group of benzimidazole. This compound inhabits gastric acid formati...
ABSTRACT Ilaprazole is a Proton Pump Inhibitor (PPI), an anti-acidic drugused in the treatment of d...
Background: A proton pump inhibitor is an acid labile drug which degrades at stomach pH 1.2. Delayed...
In an effort to reduce production costs, a simple, direct compression delayed release formulation co...
Absorption of drugs with a limited absorption window in the gastrointestinal tract (GIT) is low. Gas...
The research focuses on the development of multiparticulate delivery system for acid-labile Lansopra...
The Current scientific work would be “Design, Progress and In-Vitro Categorization like Lansoprazole...
Abstract: Pantoprazole is a proton pump inhibitor, belonging to the group of benzimidazoles and is u...
Objective: Lansoprazole an proton pump inhibitor, degrades in acidic environment, hence protection o...
Dexrabeprazole sodium (DEX) is R (+)-isomer of rabeprazole. DEX has been used in the treatment of ga...
Background: Dual delayed-release dexlansoprazole is approved for use in adults as a 30 mg orally dis...
Targeted release of bilayer tablet for combination therapy of pantoprazole sodium and ondansetron hy...
Duodenal ulcers are part of a broader disease state categorized as peptic ulcer diseaseWhile most du...
Background: The pharmacokinetics and pharmacodynamics of a novel orally disintegrating tablet (ODT) ...
The goal of this study is to develop a long-acting Lansoprazole delivery system. Lansoprazole belong...
proton pump inhibitor belongs to group of benzimidazole. This compound inhabits gastric acid formati...
ABSTRACT Ilaprazole is a Proton Pump Inhibitor (PPI), an anti-acidic drugused in the treatment of d...
Background: A proton pump inhibitor is an acid labile drug which degrades at stomach pH 1.2. Delayed...
In an effort to reduce production costs, a simple, direct compression delayed release formulation co...
Absorption of drugs with a limited absorption window in the gastrointestinal tract (GIT) is low. Gas...
The research focuses on the development of multiparticulate delivery system for acid-labile Lansopra...
The Current scientific work would be “Design, Progress and In-Vitro Categorization like Lansoprazole...
Abstract: Pantoprazole is a proton pump inhibitor, belonging to the group of benzimidazoles and is u...
Objective: Lansoprazole an proton pump inhibitor, degrades in acidic environment, hence protection o...
Dexrabeprazole sodium (DEX) is R (+)-isomer of rabeprazole. DEX has been used in the treatment of ga...
Background: Dual delayed-release dexlansoprazole is approved for use in adults as a 30 mg orally dis...
Targeted release of bilayer tablet for combination therapy of pantoprazole sodium and ondansetron hy...
Duodenal ulcers are part of a broader disease state categorized as peptic ulcer diseaseWhile most du...
Background: The pharmacokinetics and pharmacodynamics of a novel orally disintegrating tablet (ODT) ...